ASTRAZENECA PICKS UP 2ND ARRAY COMPOUND

Array BioPharma Inc. said Tuesday that AstraZeneca PLC selected another of the drugs they are developing to enter human trials, triggering a $1 million payment from AstraZeneca to Array. The two pharmaceutical companies agreed in 2003 to develop the first compound, a potential cancer therapy called ARRY-142886, and to collaborate on developing other therapies. That first treatment is currently in early stage studies.
MSN Money